Promoting Life-Saving New Therapies for Neonates Act of 2016
Latest action · May 13, 2016 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 10, 2016
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Promoting Life-Saving New Therapies for Neonates Act of 2016
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to award the sponsor of a new drug or biological product for the treatment of newborns a neonatal drug exclusivity voucher upon approval of the medication. A neonatal drug exclusivity voucher is a transferable voucher for a one-year extension of all existing patents and marketing exclusivities for a brand name medication. For a sponsor to be eligible for a voucher, the new medication must: (1) treat a condition identified in the Priority List of Critical Needs for Neonates required under this bill, and (2) have been studied in newborns.
A voucher may be revoked if the new medication is not marketed in the United States within one year of approval.
A voucher may not be used: (1) to extend the marketing exclusivity period for a drug for which the FDA requires an assessment of the safety and effectiveness in newborns, or (2) on the same product as a priority review voucher.
A sponsor intending to use a voucher must notify the FDA at least 15 months before the expiration of the patents or exclusivity to be extended.
The Government Accountability Office must study the effectiveness of this voucher program.Cosponsors 33
Members who signed on, in the order they did. Signatures ran from May 10, 2016 to Sep 28, 2016; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NM | Ben Ray Luján | Original | May 10, 2016 |
| D-NC | Alma S. Adams | May 23, 2016 | |
| D-VA | Gerald E. Connolly | Jun 8, 2016 | |
| D-NJ | Bill Pascrell, Jr. | Jun 10, 2016 | |
| R-ME | Bruce Poliquin | Jun 10, 2016 | |
| D-TX | Marc A. Veasey | Jun 10, 2016 | |
| R-KY | Brett Guthrie | Jun 16, 2016 | |
| D-NJ | Donald Norcross | Jun 16, 2016 | |
| D-CA | Pete Aguilar | Jun 16, 2016 | |
| D-AZ | Ruben Gallego | Jun 16, 2016 | |
| D-NJ | Albio Sires | Jul 5, 2016 | |
| D-NY | Kathleen M. Rice | Jul 5, 2016 | |
| D-FL | Patrick Murphy | Jul 5, 2016 | |
| R-WI | Sean P. Duffy | Jul 5, 2016 | |
| R-WV | Evan H. Jenkins | Jul 6, 2016 | |
| R-NJ | Leonard Lance | Jul 6, 2016 | |
| R-WV | Alexander X. Mooney | Jul 12, 2016 | |
| D-NE | Brad Ashford | Jul 12, 2016 | |
| D-CA | Grace F. Napolitano | Jul 12, 2016 | |
| D-MA | Seth Moulton | Jul 12, 2016 | |
| D-IL | Bobby L. Rush | Jul 13, 2016 | |
| R-FL | Gus M. Bilirakis | Jul 13, 2016 | |
| R-NY | Peter T. King | Jul 13, 2016 | |
| R-MI | Mike Bishop | Jul 14, 2016 | |
| D-WA | Derek Kilmer | Sep 6, 2016 | |
| D-NY | Steve Israel | Sep 6, 2016 | |
| D-CA | Tony Cárdenas | Sep 6, 2016 | |
| R-PA | Mike Kelly | Sep 20, 2016 | |
| R-IL | Robert J. Dold | Sep 20, 2016 | |
| D-CA | Scott H. Peters | Sep 22, 2016 | |
| D-IA | David Loebsack | Sep 27, 2016 | |
| D-NC | David E. Price | Sep 28, 2016 | |
| R-MN | Erik Paulsen | Sep 28, 2016 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred May 10, 2016 |
| Health Subcommittee | Referred May 13, 2016 |
Actions 3
Everything that happened, newest first.
- May 13, 2016Referred to the Subcommittee on Health.
- May 10, 2016Introduced in House
- May 10, 2016Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 162, no. 73, May 10, 2016, page H2214.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 2041 | Promoting Life-Saving New Therapies for Neonates Act of 2015 | Related bill | Sep 16, 2015 |
| HR 2641 | Promoting Life-Saving New Therapies for Neonates Act of 2017 | Reintroduced Bill | May 26, 2017 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To promote the development of safe drugs for neonates.
- Short Titles as Introduced
- Promoting Life-Saving New Therapies for Neonates Act of 2016
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Child health
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Food and Drug Administration (FDA)
- Government studies and investigations
- Health
- Health promotion and preventive care
- Medical research
Text 1
Each version as it was printed, newest first.
- May 10, 2016Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.